HC Wainwright & Co. Maintains Buy on Cullinan Therapeutics, Raises Price Target to $30
Benzinga Newsdesk 6 months ago
NewsPrice TargetAnalyst Ratings
HC Wainwright & Co. analyst Robert Burns maintains Cullinan Therapeutics (NASDAQ:CGEM) with a Buy and raises the price target from $27 to $30.
HC Wainwright & Co. analyst Robert Burns maintains Cullinan Therapeutics (NASDAQ:CGEM) with a Buy and raises the price target from $27 to $30.